Cognito Reports Mild Alzheimer’s Benefit in 40Hz Trial That Missed Overall Endpoint

Cognito Therapeutics reported that its light-and-sound device slowed decline in a mild Alzheimer’s subgroup, while the full 663-person trial missed its primary endpoint.

More News